Sanofi and Regeneron acknowledged that testing their ... quality of life and respiratory symptom scores in what looks like a comprehensive win for the antibody. Already raking in $9 billion ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex landscape of challenges and opportunities in recent months. According to ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...